New drug combo targets Hard-to-Treat cancers
NCT ID NCT07222267
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 29 times
Summary
This early-stage study tests a new drug called BG-75202, alone or with other treatments, in people with advanced breast cancer or other solid tumors that have stopped responding to standard care. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 86 participants will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
-
Blacktown Cancer and Haematology Centre
RECRUITINGBlacktown, New South Wales, NSW 2148, Australia
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100021, China
-
Cancer Research South Australia
RECRUITINGAdelaide, South Australia, SA 5000, Australia
-
Chris Obrien Lifehouse
RECRUITINGCamperdown, New South Wales, NSW 2050, Australia
-
Fondazione Policlinico Universitario Agostino Gemelli
RECRUITINGRoma, 00168, Italy
-
Fudan University Shanghai Cancer Centerpudong
RECRUITINGShanghai, Shanghai Municipality, 201321, China
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, Heilongjiang, 150000, China
-
Hospital Clinico San Carlos
RECRUITINGMadrid, 28240, Spain
-
Hospital Universitario 12 de Octubre
RECRUITINGMadrid, 28041, Spain
-
Hospital Universitario Vall Dhebron
RECRUITINGBarcelona, 08035, Spain
-
Hospital Universitario Virgen de La Victoria
RECRUITINGMálaga, 29010, Spain
-
Istituto Clinico Humanitas
RECRUITINGRozzano, 20089, Italy
-
Istituto Europeo Di Oncologia
RECRUITINGMilan, 20141, Italy
-
Istituto Nazionale Tumori Fondazione G Pascale
RECRUITINGNaples, 80131, Italy
-
Jiangsu Province Hospital Longjiang Branch
RECRUITINGNanjing, Jiangsu, 210036, China
-
Next Oncology Austin
RECRUITINGAustin, Texas, 78758, United States
-
Next Oncology Barcelona
RECRUITINGBarcelona, 8023, Spain
-
Peter Maccallum Cancer Centre
RECRUITINGMelbourne, Victoria, VIC 3000, Australia
-
Sun Yat Sen University Cancer Center Huangpu Branch
RECRUITINGGuangzhou, Guangdong, 510555, China
-
The University of Texas Md Anderson Cancer Center
RECRUITINGHouston, Texas, 77030-4009, United States
-
Tianjin Medical University Cancer Institute and Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
-
University of Alabama At Birmingham Hospital
RECRUITINGBirmingham, Alabama, 35294-0004, United States
-
Washington University in St Louis
RECRUITINGSt Louis, Missouri, 63110-1010, United States
-
Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.